Your browser doesn't support javascript.
loading
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada, Masaya; Imagawa, Jun; Tanaka, Hideo; Nakamae, Hirohisa; Hino, Masayuki; Murai, Kazunori; Ishida, Yoji; Kumagai, Takashi; Sato, Seiichi; Ohashi, Kazuteru; Sakamaki, Hisashi; Wakita, Hisashi; Uoshima, Nobuhiko; Nakagawa, Yasunori; Minami, Yosuke; Ogasawara, Masahiro; Takeoka, Tomoharu; Akasaka, Hiroshi; Utsumi, Takahiko; Uike, Naokuni; Sato, Tsutomu; Ando, Sachiko; Usuki, Kensuke; Mizuta, Syuichi; Hashino, Satoshi; Nomura, Tetsuhiko; Shikami, Masato; Fukutani, Hisashi; Ohe, Yokiko; Kosugi, Hiroshi; Shibayama, Hirohiko; Maeda, Yasuhiro; Fukushima, Toshihiro; Yamazaki, Hirohito; Tsubaki, Kazuo; Kukita, Toshimasa; Adachi, Yoko; Nataduka, Toshiki; Sakoda, Hiroto; Yokoyama, Hisayuki; Okamoto, Takahiro; Shirasugi, Yukari; Onishi, Yasushi; Nohgawa, Masaharu; Yoshihara, Satoshi; Morita, Satoshi; Sakamoto, Junichi; Kimura, Shinya.
Afiliação
  • Okada M; Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
  • Imagawa J; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Tanaka H; Department of Hematology, Hiroshima City Asa Hospital, Hiroshima, Japan.
  • Nakamae H; Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Hino M; Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Murai K; Department of Hematology and Oncology, Iwate Medical University, Morioka, Japan.
  • Ishida Y; Department of Hematology and Oncology, Iwate Medical University, Morioka, Japan.
  • Kumagai T; Department of Hematology, Ohme Municipal General Hospital, Tokyo, Japan.
  • Sato S; Department of Internal Medicine, Fujimoto General Hospital, Miyakonojo, Japan.
  • Ohashi K; Division of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo, Japan.
  • Sakamaki H; Division of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo, Japan.
  • Wakita H; Division of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
  • Uoshima N; Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan.
  • Nakagawa Y; Department of Hematology, Japanese Red Cross Medical Centre, Tokyo, Japan.
  • Minami Y; Division of Blood Transfusion/Division of Medical Oncology and Haematology, Kobe University Hospital, Kobe, Japan.
  • Ogasawara M; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Takeoka T; Division of Hematology and Immunology, Otsu Red Cross Hospital, Otsu, Japan.
  • Akasaka H; Department of Hematology, Shinko Hospital, Kobe, Japan.
  • Utsumi T; Department of Hematology, Shiga Medical Centre for Adults, Moriyama, Japan.
  • Uike N; Division of Hematology, National Kyushu Cancer Centre, National Hospital Organization, Fukuoka, Japan.
  • Sato T; Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Ando S; Department of Haematology, Teine Keijinkai Hospital, Sapporo, Japan.
  • Usuki K; Division of Haematology, NTT Medical Centre Tokyo, Tokyo, Japan.
  • Mizuta S; Division of Haematology, Fujita Health University, Aichi, Japan.
  • Hashino S; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Nomura T; Department of Internal Medicine, Hyogo Prefectural Awaji Medical Center, Hyogo, Japan.
  • Shikami M; Department of Hematology, Daiyukai General Hospital, Aichi, Japan.
  • Fukutani H; Department of Hematology, Aichi Cancer Center Aichi Hospital, Aichi, Japan.
  • Ohe Y; Department of Hematology, Uegahara Hospital, Hyogo, Japan.
  • Kosugi H; Department of Hematology, Ogaki Municipal Hospital, Gifu, Japan.
  • Shibayama H; Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan.
  • Maeda Y; Department of Hematology, National Hospital Organization Osaka-Minami Medical Center, Osaka, Japan.
  • Fukushima T; Department of Hematology and Immunology, Kanazawa Medical University Hospital, Ishikawa, Japan.
  • Yamazaki H; Department of Hematology and Oncology, Kanazawa University Hospital, Ishikawa, Japan.
  • Tsubaki K; Department of Hematology, Nara Hospital Kinki University, Nara, Japan.
  • Kukita T; Department of Hematology, Imamura Hospital, Kagoshima, Japan.
  • Adachi Y; Department of Internal Medicine, Japan Community Health Care Organization, Kobe Central Hospital, Kobe, Japan.
  • Nataduka T; Department of Internal Medicine, Shinseikai Toyama Hospital, Toyama, Japan.
  • Sakoda H; Department of Hematology, Sumitomo Hospital, Osaka, Japan.
  • Yokoyama H; Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
  • Okamoto T; Department of Hematology, Takarazuka City Hospital, Hyogo, Japan.
  • Shirasugi Y; Department of Hematology and Oncology, Tokai University, Kanagawa, Japan.
  • Onishi Y; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
  • Nohgawa M; Department of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.
  • Yoshihara S; Department of Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Hyogo, Japan.
  • Morita S; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Sakamoto J; NPO Epidemiological and Clinical Research Information Network (ECRIN), Okazaki, Japan.
  • Kimura S; Division of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. Electronic address: shkimu@cc.saga-u.ac.jp.
Clin Lymphoma Myeloma Leuk ; 18(5): 353-360.e1, 2018 05.
Article em En | MEDLINE | ID: mdl-29610029
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases / Dasatinibe / Desprescrições / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases / Dasatinibe / Desprescrições / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Ano de publicação: 2018 Tipo de documento: Article